Dozens of US patients have sued manufacturers of GLP-1 drugs (Ozempic, Wegovy, Mounjaro) alleging inadequate warnings about rare vision loss (NAION). Currently no confirmed causal link exists—regulatory agencies in the US, EU, and Australia are actively reviewing the safety signal. Drugmakers deny liability and continue monitoring. For Thailand healthcare and pharma sectors, this signals emerging legal/regulatory risks and heightened scrutiny of GLP-1 safety profiles globally.